⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079870 | 0.78 | — | — | |
| SCHEMBL10063452 | 0.77 | — | — | |
| SCHEMBL4546381 | 0.74 | SLC6A2 (0.34) | — | |
| SCHEMBL9607530 | 0.69 | SLC6A2 (0.32) | — | |
| SCHEMBL9608969 | 0.69 | SLC6A2 (0.45) | — | |
| SCHEMBL17824655 | 0.67 | SLC6A2 (0.44) | — | |
| SCHEMBL11293802 | 0.62 | — | — | |
| SCHEMBL12904544 | 0.61 | — | — | |
| SCHEMBL18387089 | 0.61 | — | — | |
| SCHEMBL22263032 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11758805-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-11758805-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-09-12 | — | — | US | disclosed |
| WO-2023275333-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220315569-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2021222404-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN BIOTECH, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210198246-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-20090082565-A1 | METHODS OF PREPARING QUINOLONE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070032652-A1 | Methods of preparing quinolone analogs | SENHWA BIOSCIENCES, INC. (TW) | 2007-02-08 | — | — | US | disclosed |